Illumina, Inc. (NASDAQ:ILMN) announced that Philip W. Schiller has joined the company’s Board of Directors. Schiller is currently Apple’s Senior Vice President of Worldwide Marketing and is a member of Apple’s executive team responsible for the company’s product marketing, developer relations, business marketing, education marketing, international marketing and App Store programs.

Since rejoining Apple in April 1997, Schiller has helped the company create and market some of the best-selling products in the world including the Mac, iPod, iTunes, iPhone, theApp Store, Apple TV and the Apple Watch.

“Phil’s track record and global experience in bringing world-class products to market will help guide us as we continue to develop innovative new solutions for our customers,” said Francis deSouza, Illumina President and Chief Executive Officer. “His vision, integrity and passion are fully aligned with Illumina’s core values.”

Schiller has more than 30 years of marketing and management experience, including over 25 at Apple in various marketing positions; as the Vice President of Product Marketing atMacromedia, Inc. of San Francisco, Calif.; as the Director of Product Marketing atFirePower Systems, Inc. of Menlo Park, Calif.; as an Information Technology Manager at Nolan, Norton & Company of Lexington, Mass.; and as a Programmer and Systems Analyst at Massachusetts General Hospital in Boston. He graduated with a B.S. in biology from Boston College. (Original Source)

Shares of Illumina closed yesterday at $162.25, up $12.15 or 8.09%. ILMN has a 1-year high of $220.86 and a 1-year low of $127.10. The stock’s 50-day moving average is $143.42 and its 200-day moving average is $150.07.

On the ratings front, Illumina has been the subject of a number of recent research reports. In a report released yesterday, J.P. Morgan analyst Tycho Peterson maintained a Buy rating on ILMN, with a price target of $200, which represents a potential upside of 23.3% from where the stock is currently trading. Separately, on the same day, Cantor Fitzgerald’s Bryan Brokmeier reiterated a Hold rating on the stock and has a price target of $165.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Tycho Peterson and Bryan Brokmeier have a total average return of 13.4% and 2.9% respectively. Peterson has a success rate of 64.8% and is ranked #281 out of 4087 analysts, while Brokmeier has a success rate of 52.6% and is ranked #1164.

Overall, one research analyst has rated the stock with a Sell rating, 4 research analysts have assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $180.00 which is 10.9% above where the stock closed yesterday.

Illumina, Inc. develops, manufactures and markets integrated systems for the analysis of genetic variation and function. The company provides sequencing and array-based solutions for genetic analysis in addition to selling products, it provide genotyping, NIPT and whole-genome sequencing services. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies.